Skip to content
NewsBlazeIN – Lifestyle
Author:
Jaguar Health, Inc.
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
October 6, 2026
Jaguar Health Announces a Special Stock Dividend
October 2, 2026
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health’s Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
September 29, 2026
Jaguar Health Receives Fee Waivers from FDA
September 22, 2026
Jaguar Health, Inc. Announces Reverse Stock Split
September 15, 2026
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health’s Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
September 10, 2026
Neonorm Dog Now on Amazon: Jaguar Health Digestive Support
September 8, 2026
Additional Infant Patient to Receive Jaguar Health’s Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
September 4, 2026
Commercial Launch Initiated for Neonorm Dog, Jaguar Health’s Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
August 26, 2026
Jaguar Health Reports Second Quarter 2026 Financials
August 19, 2026
1
2
3
4
Next Page
→